Yue Wu, PhD Yue Wu, PhD

Yue Wu

PhD

About Yue Wu

Biography:

Yue Wu, PhD, earned his doctoral degree in Microbiology from Beijing Agricultural University, China, in 1998. Dr. Wu joined the staff of Roswell Park Comprehensive Cancer Center in 2003 as a postdoctoral research affiliate in the Department of Cancer Prevention and Control, within the division of Cancer Prevention and Population Sciences. He was appointed to Affiliate Member in 2007, and HRI Scientist, Assistant Professor of Oncology in 2008.

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Department of Urology
  • HRI Scientist

Background

Education and Training:

  • 1998 - PhD - Microbiology, Beijing Agricultural University, Beijing, China

Professional Memberships:

  • American Association for Cancer Research
  • American Urological Association
  • Society for Basic Urologic Research

Research

Research Overview:

Dr. Wu’s research interest is in androgen metabolism and androgen receptor signaling in prostate cancer. Specifically, his research projects are focused on prostatic androgen trafficking and metabolism by prostatic epithelial cells and cancer cells, and how androgen metabolism affects biology and clinical characteristics of prostate cancer. The ultimate goal is to delineate mechanisms underlying the progression of prostate cancer to castration recurrent disease, and to identify novel modalities to prevent or treat castration recurrent prostate cancer.

Current active research initiatives include:

  1. Identification of cell membrane-located transporters that are critical for prostate cancer cells to obtain androgens from the circulation, and the potential of targeting these transporters to achieve complete androgen deprivation.
  2. To examine the role of genetic variations of androgen transporters in racial disparity in prostate cancer aggressiveness.
  3. To evaluate the importance of adrenal androgen uptake and metabolism to castration-recurrent prostate cancer, and to identify approaches to specifically deprive cancer cells of adrenal androgens.
  4. To understand the role of prostatic endothelium in regulation of blood – prostate transit of androgens, and to develop prostate-specific approaches for organ-specific androgen deprivation.

Publications

Full Publications list on PubMed
  • Ou L, Wu Y, Ip C, Meng X, Hsu YC, Ip MM. Apoptosis induced by t10,c12-conjugated linoleic acid is mediated by an atypical endoplasmic reticulum stress response. J Lipid Res. 2008 May;49(5):985-94. doi: 10.1194/jlr.M700465-JLR200. Epub 2008 Feb 8. PMID: 18263853; PMCID: PMC2311448.
  • Wu Y, Fabritius M, Ip C. Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer. Cancer Biol Ther. 2009 Jan;8(2):146-52. doi: 10.4161/cbt.8.2.7087. Epub 2009 Feb 1. PMID: 19182512; PMCID: PMC2714659.
  • Chhipa RR, Lee KS, Onate S, Wu Y, Ip C. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res. 2009 Sep;7(9):1543-52. doi: 10.1158/1541-7786.MCR-08-0546. Epub 2009 Sep 8. PMID: 19737972; PMCID: PMC2774234.
  • Cheng J, Wu Y, Mohler JL, Ip C. The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biol Ther. 2010 Jun 15;9(12):1033-42. doi: 10.4161/cbt.9.12.11876. Epub 2010 Jun 24. PMID: 20404538; PMCID: PMC2939298.
  • Chhipa RR, Wu Y, Mohler JL, Ip C. Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cell Signal. 2010 Oct;22(10):1554-61. doi: 10.1016/j.cellsig.2010.05.024. Epub 2010 Jun 4. PMID: 20570728; PMCID: PMC4712644.
  • Wu Y, Chhipa RR, Cheng J, Zhang H, Mohler JL, Ip C. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res. 2010 Oct;30(10):3895-901. PMID: 21036700; PMCID: PMC4355915.
  • Chhipa RR, Wu Y, Ip C. AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. Cell Signal. 2011 Sep;23(9):1466-72. doi: 10.1016/j.cellsig.2011.04.008. Epub 2011 Apr 28. PMID: 21554950; PMCID: PMC3115439.
  • Wu Y, Chhipa RR, Zhang H, Ip C. The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biol Ther. 2011 May 15;11(10):902-9. doi: 10.4161/cbt.11.10.15187. Epub 2011 May 15. PMID: 21386657; PMCID: PMC3116931.
  • Wu Y, Godoy A, Azzouni F, Wilton JH, Ip C, Mohler JL. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. Prostate. 2013 Sep;73(13):1470-82. doi: 10.1002/pros.22694. Epub 2013 Jun 27. PMID: 23813697; PMCID: PMC3999702.
  • Chhipa RR, Halim D, Cheng J, Zhang HY, Mohler JL, Ip C, Wu Y. The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. Prostate. 2013 Oct;73(14):1483-94. doi: 10.1002/pros.22696. Epub 2013 Jun 28. PMID: 23813737; PMCID: PMC3992475.